You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 31, 2024

ravicti Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Ravicti, and what generic alternatives are available?

Ravicti is a drug marketed by Horizon Therap Us and is included in one NDA. There are fifteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and fourteen patent family members in twenty-nine countries.

The generic ingredient in RAVICTI is glycerol phenylbutyrate. There are fifty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the glycerol phenylbutyrate profile page.

DrugPatentWatch® Generic Entry Outlook for Ravicti

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (glycerol phenylbutyrate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ravicti?
  • What are the global sales for ravicti?
  • What is Average Wholesale Price for ravicti?
Drug patent expirations by year for ravicti
Drug Prices for ravicti

See drug prices for ravicti

Recent Clinical Trials for ravicti

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Weizmann Institute of SciencePhase 2/Phase 3
Kaplan Medical CenterPhase 2/Phase 3
Children's Hospital of PhiladelphiaPhase 1/Phase 2

See all ravicti clinical trials

Pharmacology for ravicti
Paragraph IV (Patent) Challenges for RAVICTI
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
RAVICTI Oral Liquid glycerol phenylbutyrate 1.1 g/mL 203284 1 2013-11-19

US Patents and Regulatory Information for ravicti

ravicti is protected by fifteen US patents and one FDA Regulatory Exclusivity.

Patents protecting ravicti

Methods of therapeutic monitoring of nitrogen scavenging drugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF A UREA CYCLE DISORDER

Methods of therapeutic monitoring of nitrogen scavenging drugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF A UREA CYCLE DISORDER

Methods of therapeutic monitoring of nitrogen scavenging drugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF A UREA CYCLE DISORDER

Methods of therapeutic monitoring of nitrogen scavenging drugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF A UREA CYCLE DISORDER

Methods of therapeutic monitoring of nitrogen scavenging drugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF A UREA CYCLE DISORDER

Methods of therapeutic monitoring of nitrogen scavenging drugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF A UREA CYCLE DISORDER

Methods of therapeutic monitoring of nitrogen scavenging drugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF A UREA CYCLE DISORDER

Treatment of urea cycle disorders in neonates and infants
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF A UREA CYCLE DISORDER

Methods of therapeutic monitoring of nitrogen scavenging
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER

Methods of treatment using ammonia-scavenging drugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER

Methods of therapeutic monitoring of nitrogen scavenging drugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF A UREA CYCLE DISORDER

Methods of therapeutic monitoring of nitrogen scavenging drugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF A UREA CYCLE DISORDER

Methods of therapeutic monitoring of phenylacetic acid prodrugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER

Methods of therapeutic monitoring of nitrogen scavenging drugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF A UREA CYCLE DISORDER

Methods of therapeutic monitoring of nitrogen scavenging drugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF A UREA CYCLE DISORDER

FDA Regulatory Exclusivity protecting ravicti

FOR USE AS A NITROGEN-BINDING AGENT FOR CHRONIC MANAGEMENT OF PEDIATRIC PATIENTS >=2 MONTHS AND < 2 YEARS OF AGE WITH UREA CYCLE DISORDERS (UCDS) WHO CANNOT BE MANAGED BY DIETARY PROTEIN RESTRICTION AND/OR AMINO ACID SUPPLEMENTATION ALONE
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Horizon Therap Us RAVICTI glycerol phenylbutyrate LIQUID;ORAL 203284-001 Feb 1, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Horizon Therap Us RAVICTI glycerol phenylbutyrate LIQUID;ORAL 203284-001 Feb 1, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Horizon Therap Us RAVICTI glycerol phenylbutyrate LIQUID;ORAL 203284-001 Feb 1, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Horizon Therap Us RAVICTI glycerol phenylbutyrate LIQUID;ORAL 203284-001 Feb 1, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Horizon Therap Us RAVICTI glycerol phenylbutyrate LIQUID;ORAL 203284-001 Feb 1, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Horizon Therap Us RAVICTI glycerol phenylbutyrate LIQUID;ORAL 203284-001 Feb 1, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Horizon Therap Us RAVICTI glycerol phenylbutyrate LIQUID;ORAL 203284-001 Feb 1, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for ravicti

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Immedica Pharma AB Ravicti glycerol phenylbutyrate EMEA/H/C/003822
Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements).
Authorised no no yes 2015-11-26
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for ravicti

See the table below for patents covering ravicti around the world.

Country Patent Number Title Estimated Expiration
Denmark 2760479 ⤷  Sign Up
Brazil 112014026138 métodos de monitoramento terapêutico de pró-fármacos de ácido fenilacético ⤷  Sign Up
Japan 2014102255 TREATMENT METHOD USING AMMONIA-SCAVENGING DRUGS ⤷  Sign Up
European Patent Office 3222275 PROCÉDÉS DE SURVEILLANCE THÉRAPEUTIQUE DE PROMÉDICAMENTS À BASE D'ACIDE PHÉNYLACÉTIQUE (METHODS OF THERAPEUTIC MONITORING OF PHENYLACETIC ACID PRODRUGS) ⤷  Sign Up
Lithuania 2330892 ⤷  Sign Up
Hungary E035220 ⤷  Sign Up
Hungary E032726 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ravicti

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2330892 93351 Luxembourg ⤷  Sign Up PRODUCT NAME: GLYCEROL PHENYLBUTYRATE; AUTHORISATION NUMBER AND DATE: EU/1/15/1062
2330892 635 Finland ⤷  Sign Up
2330892 2016023 Norway ⤷  Sign Up PRODUCT NAME: GLYCEROLFENYLBUTYRAT; REG. NO/DATE: EU/1/15/1062 20151210
2330892 359 5034-2016 Slovakia ⤷  Sign Up PRODUCT NAME: GLYCEROLFENYLBUTYRAT; REGISTRATION NO/DATE: EU/1/15/1062 20151201
2330892 PA2016041 Lithuania ⤷  Sign Up PRODUCT NAME: GLICEROLIO FENILBUTIRATAS; REGISTRATION NO/DATE: EU/1/15/1062 20151127
2330892 C20160044 00204 Estonia ⤷  Sign Up PRODUCT NAME: GLUETSEROOLFENUEUELBUTUERAAT;REG NO/DATE: EU/1/15/1062 01.12.2015
2330892 122016000107 Germany ⤷  Sign Up PRODUCT NAME: GLYCEROLPHENYLBUTYRAT; REGISTRATION NO/DATE: EU/1/15/1062 20151127
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.